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Hierarchy of effective KT strategies Barriers 
What do you think funders/regulators/clinicians should know about your work? Do they? 
Technical hurdle or excuse for lack of bench to bedside KT? 
•Some argue that true proteomics is too big for one lab to really handle, so it needs more 
collaboration.  However, this kind of collaboration is still rare: “Aren’t really many very good 
examples of true proteomics projects” 
•But is this an intractable problem that will only be solved through mega projects? 
•Some argue, no, that they can find pieces that can lead to clinical application, but they have to 
frame their piece of proteomics research carefully. 
Reasons for barriers? 
Why isn’t proteomics a priority of funding agencies?  
•“They don’t believe in (proteomics) at all.  There are no proteomics panels at [funder].  There are lots 
of genomics panels.” 
•Given the economic climate, many governments want clearer deliverables, leading to a lack of interest 
in proteomics’ potential:  “It’s a really bad time to be trying to do something that’s an exploratory, data 
generation project with no clear deliverable in terms of benefits to the people providing the money.” 
•Some individuals also commented that they thought policy makers and funders might see proteomics 
as a kind of ‘lesser’ genomics, as both require large projects, but proteomics is less established, so 
therefore more of a gamble.  
 
 
Is proteomics research creating “data cemeteries”? 
•Some commented that proteomics research is often not organized with enough participation 
of clinicians (partially a funding issue), which hampers its ability to create clinical applications: 
“One day when the field will have the clinicians at the forefront, in my view, that’s when the 
real clinical discoveries are going to be made” 
Standards necessary or distractions at this stage? 
•Some argue that standards are necessary for collaboration between scientists and publication 
(e.g. data reporting standards) and also for application (e.g. laboratory sampling & handling 
standards).  However, others argue that the technology is still developing, as are the skills of 
researchers – so they are merely a distraction. “You want to be sure you can at least 
characterize the proteins, right?  So we sent these [samples] around the world to groups that 
were getting in millions of dollars in grant per year.  And most of them couldn’t do this.  I 
mean, come on!  An F1 driver has to be able to drive the car around the circuit and not crash 
into the first pole, right?” 
KEY ISSUE 
Gaining support for proteomics science requires effective knowledge translation. 
Knowledge translation (KT) processes turn the evidence generated by scientific discovery into recommendations for 
clinical applications, funding priorities, and policy/regulatory reforms.  Clinicians, regulators, and funders need to understand why 
emerging proteomics knowledge is relevant, and what are the potential applications of that knowledge.  A lack of clarity remains about what 
KT means.  
PROJECT  
DESCRIPTION  
This is a multi-year project on standardization in health regulation, funded by the Canadian Institutes of Health Research.  We interview 
proteomics researchers and funders to ask the following key questions: 
KEY QUESTIONS 
Q1:  What key areas do proteomics scientists,  funders, and  regulators see as potential areas of miscommunication? 
Q2:  How do proteomics scientists view the process of knowledge translation? 
Q3:  How is proteomics knowledge translated? 
Q4:  What role does standardization have in proteomics KT? 
WHAT DO 
PROTEOMICS 
RESEARCHERS NEED 
TO KNOW ABOUT KT? 
Simple dissemination – publishing or presenting results in conferences – is often a part of an end-of-grant KT strategy, but many argue that 
effective KT can only happen if the research has a measurable impact on the policy/funding environment or on health 
outcomes. Have funding bodies changed their priorities recognizing the significance of proteomics research?  Are policy makers engaging 
with proteomics to understand the long-term implications for health care?  Do clinicians understand the potential implications of the science 
for their patients? We present preliminary findings from our interviews on barriers to effective KT in proteomics science. 
Priorities of funding agencies 
Complexity of proteomics science 
Organization of proteomics 
research 
Role of standards 
STRONG KT 
Collaborative interprofessional 
curriculum development 
Government briefings with key decision 
makers 
Public meetings / science cafes 
BASIC KT  
Dissemination at scientific conferences 
Publication in peer-reviewed journals 
Media releases 
INTEGRATED KT 
Knowledge users participate  
throughout the research process to: 
Help define questions 
Identify potential applications (e.g. clinicians) 
Provide feedback for iterative refinement  
 
